Founded in 2021, 1Cell.Ai operates in Health Tech offering precision oncology liquid biopsy diagnostics through the development of CTC-based, single-cell multi-omics lab developed tests. The company f...
Funding stage:
Series A
Last funding:
21/11/2024
Total funding:
$16.00 Mn+
Revenue:
Investors
1Cell.Ai: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders4
Latest Filing Date30 March 2025- Funding Events1
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of 1Cell.Ai
As of 31 March 2025, 1Cell.Ai's equity is held by 4 shareholders, with the top three being OneCell Diagnostics Inc, Tenacity Ventures Fund I, and Jayant Khandare.
OneCell Diagnostics Inc holds the largest stake in 1Cell.Ai at 79.8% as of 31 March 2025.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links